1. Scrip
  2. >>Business
  3. >>Deals

Bicycle Partners With Biogen Spinout Against Rare Blood Disorders

 
• By Lucie Ellis-Taitt

Bicycle Therapeutics and Biogen spinoff Bioverativ have teamed up to develop novel treatments for hemophilia and sickle cell disease under a multi-million-dollar discovery and development agreement.

Sickle cell anemia, 3D illustration showing blood vessel with normal and deformated crescent-like red blood cells
Bicycle and Bioverativ strike discovery & development deal for blood disorder drugs

Bicycle Therapeutics Ltd. has signed a deal with US biotech Bioverativ Inc., a spinout from Biogen Inc., worth more than $420m in upfront and milestone payments; the pair will develop and commercialize innovative therapies for hemophilia and sickle cell disease.

Through the collaboration the companies will identify and develop so-called "Bicycles" to treat rare blood disorders

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

More from Business